Recombinant factor VII (activated) for haemorrhagic complications of severe sepsis treated with recombinant protein C (activated)

被引:1
|
作者
Michalska-Krzanowska, Grazyna
Czuprynska, Maria
机构
[1] Clin Hosp 2, Dept Anaesthesiol & Intens Care, PL-70111 Szczecin, Poland
[2] M Curie Hosp, Dept Anaesthesiol & Intens Care, Szczecin, Poland
关键词
activated protein C; recombinant factor Vlla; septic shock; sepsis;
D O I
10.1159/000093643
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report on 2 cases of severe sepsis treated with drotrecogin-alpha (Xigris, Eli Lilly), where massive perioperative haemorrhage required administration of recombinant factor Vila. The first patient developed severe sepsis after surgery (laparoscopic cholecystectomy, laparotomy due to peritonitis). After 18 h of treatment with Xigris, the patient developed massive, refractory gastrointestinal and abdominal bleeding. Effective haemostasis was achieved after 2 doses of NovoSeven (Novo Nordisk, Denmark). The patient died due to a cerebral bleed. The second patient developed septic shock in the course of pyelonephritis and right hydronephrosis. She was treated with Xigris and nephrectomy. Uncontrollable perioperative bleeding was effectively treated with 2 doses of NovoSeven. The patient survived. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:126 / 130
页数:5
相关论文
共 50 条
  • [1] Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?
    Kessler, C
    INTENSIVE CARE MEDICINE, 2002, 28 (Suppl 2) : S228 - S234
  • [2] Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?
    Craig Kessler
    Intensive Care Medicine, 2002, 28 : s228 - s234
  • [3] Human recombinant activated protein C for severe sepsis
    Marti-Carvajal, Arturo J.
    Sola, Ivan
    Lathyris, Dimitrios
    Felipe Cardona, Andres
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (03):
  • [4] Recombinant human activated protein C in severe sepsis
    Mann, HJ
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 : S19 - S23
  • [5] Recombinant human activated protein C for severe sepsis
    Ott, A
    Verbrugh, HA
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03): : 220 - 220
  • [6] Human recombinant activated protein C for severe sepsis
    Marti-Carvajal, Arturo J.
    Sola, Ivan
    Lathyris, Dimitrios
    Felipe Cardona, Andres
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (04):
  • [7] Human recombinant activated protein C for severe sepsis
    Marti-Carvajal, A.
    Salanti, G.
    Cardona, A. F.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03):
  • [8] Human recombinant activated protein C for severe sepsis
    Marti-Carvajal, A.
    Salanti, G.
    Cardona, A. F.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (01):
  • [9] Human recombinant activated protein C for severe sepsis
    Marti-Carvajal, Arturo J.
    ANESTHESIA AND ANALGESIA, 2008, 106 (01): : 346 - 346
  • [10] Severe obstetric bleeding treated with recombinant activated factor VII (rFVIIa)
    Segal, S
    Shemesh, IY
    Blumental, R
    Yoffe, B
    Laufer, N
    Ezra, Y
    Levy, I
    Mazor, M
    Martinowitz, U
    2ND WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY, 2001, : 43 - 46